(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of -4.48% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 6.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 55.62%.
Harvard Bioscience's revenue in 2025 is $91,397,000.On average, 1 Wall Street analysts forecast HBIO's revenue for 2025 to be $3,859,860,026, with the lowest HBIO revenue forecast at $3,859,860,026, and the highest HBIO revenue forecast at $3,859,860,026.
In 2026, HBIO is forecast to generate $4,222,412,743 in revenue, with the lowest revenue forecast at $4,222,412,743 and the highest revenue forecast at $4,222,412,743.